Evaluation of side effects due to @entity1088 in long-term treatment of XXXX .

@entity1 @entity1088 @entity4164 @entity3028 @entity591 @entity161 @entity71586 @entity716 @entity236 @entity551
17 @entity1 (13 males and 4 females) were examined for side effects due to long-term treatment with @entity71586 ( @entity1088 ) with emphasis on alterations in @entity236 . 16 @entity1 were @entity161 , one @entity1 was diagnosed @entity716 e causa dubia. The age range was 25-68 years, with an average of 38.2 years. The daily @entity1088 dose varied from 225 to 800 mg with a total intake during the trial period of 149.1-891.6 g yielding an average of 479.8 g. The treatment period varied from 20 to 51 months, with an average of 35.9 months. None of the @entity1 had to discontinue the treatment because of side effects. The laboratory data including hematological, and nephrological parameters revealed no significant changes related to @entity1088 treatment within the treatment period. No changes were observed in ECG. 12 @entity1 experienced side effects, 8 of them receiving concomitant psycholeptic medication. 9 @entity1 complained of temporary fatigue and 5 of these experienced continuous drowsiness. There were 8 cases of @entity4164 and two cases of increased appetite. One @entity1 developed light @entity591 and one @entity1 @entity551 . @entity1088 is known to be an effective anti- @entity716 drug, but due to reports of @entity3028 in 16 Finnish @entity1 the drug was withdrawn from the Danish market in 1975 although later its use was merely restricted to special cases. This study does not indicate that @entity1088 contains greater risk of clinical side effects than commonly used psycholeptic drugs.
